Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 2CNS 2Sarcoma 1Other solid neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 124Multiple Myeloma 83Precursor Cell Lymphoblastic Leukemia-Lymphoma 74Lymphoma 73Lymphoma, Non-Hodgkin 65Leukemia 65Myelodysplastic Syndromes 56Hodgkin Disease 53Lymphoma, Large B-Cell, Diffuse 37Lymphoma, Mantle-Cell 33Breast Neoplasms 31Leukemia, Lymphocytic, Chronic, B-Cell 30Burkitt Lymphoma 30Neuroblastoma 29Lymphoma, Follicular 26Leukemia, Myelogenous, Chronic, BCR-ABL Positive 26Recurrence 24Sarcoma 18Neoplasms, Plasma Cell 18Hematologic Neoplasms 18Central Nervous System Neoplasms 18Lymphoma, B-Cell, Marginal Zone 17Leukemia, Biphenotypic, Acute 16Myeloproliferative Disorders 15Lymphoma, Large-Cell, Immunoblastic 15Congenital Abnormalities 15Brain Neoplasms 14Leukemia, Myelomonocytic, Chronic 13Anemia, Refractory, with Excess of Blasts 13Medulloblastoma 12

Interventions

eltrombopag 14romiplostim 7avatrombopag 6Cytarabine 6Platelet Transfusion 5Filgrastim 4Etoposide 4Carboplatin 4oprelvekin 3Tranexamic Acid 3Radiotherapy 3Peripheral Blood Stem Cell Transplantation 3Daunorubicin 3Cyclophosphamide 3Busulfan 3hetrombopag 2fludarabine phosphate 2Tretinoin 2Thrombopoietin 2Lenalidomide 2Interleukin-11 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Doxorubicin 2Cyclosporine 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2sodium thiosulfate 1siltuximab 1sargramostim 1raltitrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Thrombocytopenia × Granulocyte Colony-Stimulating Factor × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

NCT00003597 2014-07-24

Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors

Children's Oncology Group

Phase 1 Completed
16 enrolled
CNSClassical hematologyDermatologicGenitourinaryGynecologicOther solid neoplasmSarcoma

Uveal Melanoma, Astrocytoma, Carcinoma, Renal Cell, Medulloblastoma, Melanoma, Neoplasms, Wilms Tumor, Neuroblastoma, Neutropenia, Retinoblastoma, Osteosarcoma, Testicular Neoplasms, Thrombocytopenia, Neuroectodermal Tumors, Primitive, Peripheral, Optic Nerve Glioma, Gestational Trophoblastic Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡